{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:44:08Z","timestamp":1780332248286,"version":"3.54.1"},"reference-count":87,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Splanchnic vein thrombosis (SVT), which includes portal, mesenteric, and splenic vein thrombosis and the Budd\u2013Chiari syndrome, is an infrequent manifestation of venous thromboembolism (VTE). Like typical site VTE, SVT is also frequently associated with cancer, particularly intra-abdominal solid malignancies and myeloproliferative neoplasms (MPNs). The clinical presentation of SVT is nonspecific. Symptoms may be related to the underlying malignancy, and thrombosis is incidentally diagnosed by imaging studies for cancer staging or follow-up in a substantial proportion of cases. The occurrence of SVT predicts worse prognosis in patients with liver or pancreatic cancer and, not uncommonly, SVT may precede the diagnosis of cancer. Therefore, the occurrence of an apparently unprovoked SVT should prompt careful patient evaluation for the presence of an underlying malignancy or MPN. Cancer patients carry a high risk of VTE extension and recurrence and long-term anticoagulant treatment is suggested in the absence of high risk of bleeding. Either LMWH or direct oral anticoagulants (DOACs) are suggested for the treatment of patients with cancer-related SVT, although limited experience is available on the use of DOACs in these settings. Vitamin K antagonists (VKAs) are suggested for the short and long-term treatment of SVT associated with MPN. This review outlines the epidemiological aspects, pathogenesis, risk factors, and diagnosis of cancer-associated SVT, and addresses questions regarding the management of this challenging condition.<\/jats:p>","DOI":"10.1055\/s-0040-1722607","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T22:42:51Z","timestamp":1623451371000},"page":"931-941","source":"Crossref","is-referenced-by-count":13,"title":["Cancer-Associated Splanchnic Vein Thrombosis"],"prefix":"10.1055","volume":"47","author":[{"given":"Omri","family":"Cohen","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Institute of Thrombosis and Hemostasis and the Amalia Biron Research Institute, Sheba Medical Center, Tel-HaShomer, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Maria","family":"Caiano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tufano","sequence":"additional","affiliation":[{"name":"Regional Reference Centre for Coagulation Disorders, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"issue":"S 01","key":"ref1","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0049-3848(16)30092-5","article-title":"Cancer associated thrombosis: risk factors and outcomes","volume":"140","author":"S Eichinger","year":"2016","journal-title":"Thromb Res"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"N B Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"J A Heit","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2014.03.041","article-title":"Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009)","volume":"127","author":"W Huang","year":"2014","journal-title":"Am J Med"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"D Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.thromres.2017.06.030","article-title":"Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses","volume":"163","author":"N Riva","year":"2018","journal-title":"Thromb Res"},{"issue":"25","key":"ref7","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood-2014-07-551515","article-title":"How I treat splanchnic vein thrombosis","volume":"124","author":"W Ageno","year":"2014","journal-title":"Blood"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","article-title":"Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry","volume":"175","author":"W Ageno","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S2352-3026(16)30020-5","article-title":"Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry","volume":"3","author":"N Riva","year":"2016","journal-title":"Lancet Haematol"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cgh.2009.09.019","article-title":"Survival and recurrence in patients with splanchnic vein thromboses","volume":"8","author":"M R Thatipelli","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"S 01","key":"ref11","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.thromres.2017.12.024","article-title":"Revisiting occult cancer screening in patients with unprovoked venous thromboembolism","volume":"164","author":"P Robin","year":"2018","journal-title":"Thromb Res"},{"issue":"S 01","key":"ref12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1538-7836.2011.04346.x","article-title":"Management of venous thromboembolism in patients with cancer","volume":"9","author":"G Agnelli","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-0035-1550429","article-title":"Risk factors, diagnosis, management, and outcome of splanchnic vein thrombosis: a retrospective analysis","volume":"41","author":"B A Derman","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2015-03-631119","article-title":"Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival","volume":"126","author":"K K S\u00f8gaard","year":"2015","journal-title":"Blood"},{"issue":"S 01","key":"ref15","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(15)50432-5","article-title":"The mechanisms of cancer-associated thrombosis","volume":"135","author":"A Falanga","year":"2015","journal-title":"Thromb Res"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.thromres.2011.07.049","article-title":"Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7","volume":"129","author":"G T Gerotziafas","year":"2012","journal-title":"Thromb Res"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.beha.2008.12.008","article-title":"Tissue factor in tumour progression","volume":"22","author":"J Rak","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/5584_2016_119","article-title":"Portal vein thrombosis after splenic and pancreatic surgery","volume":"906","author":"J Ruiz-Tovar","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"07","key":"ref19","first-page":"2364","article-title":"Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study","volume":"96","author":"H L Janssen","year":"2000","journal-title":"Blood"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/1076029613511520","article-title":"Hereditary and acquired thrombophilia in splanchnic vein thrombosis: a single-center experience","volume":"21","author":"D Mutreja","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bpg.2016.11.002","article-title":"Testing for thrombophilia in mesenteric venous thrombosis - retrospective original study and systematic review","volume":"31","author":"M Zarrouk","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"C Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"R L Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"ref25","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"D A Arber","year":"2016","journal-title":"Blood"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"E Rumi","year":"2017","journal-title":"Blood"},{"issue":"13","key":"ref27","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"T Barbui","year":"2013","journal-title":"Blood"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0039-1693477","article-title":"Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms","volume":"45","author":"D R Arachchillage","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-018-0101-8","article-title":"Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms","volume":"8","author":"V De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"J J Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bjh.12461","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms","volume":"162","author":"M Sekhar","year":"2013","journal-title":"Br J Haematol"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"V De Stefano","year":"2016","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"E Sant'Antonio","year":"2020","journal-title":"Am J Hematol"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s11239-020-02052-4","article-title":"Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation","volume":"50","author":"L Naymagon","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"02","key":"ref35","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"E Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"issue":"08","key":"ref36","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1538-7836.2007.02626.x","article-title":"Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2\u2009V6I7\u2009F status, clonality, and antiphospholipid antibodies","volume":"5","author":"B Robertson","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","article-title":"Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden","volume":"96","author":"I Bertozzi","year":"2017","journal-title":"Ann Hematol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","article-title":"Venous thromboembolism incidence in hematologic malignancies","volume":"33","author":"N Kekre","year":"2019","journal-title":"Blood Rev"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clml.2014.05.003","article-title":"Thrombosis and hemostatic abnormalities in hematological malignancies","volume":"14","author":"R Colombo","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.thromres.2011.11.034","article-title":"Hematologic malignancies and thrombosis","volume":"129","author":"F Elice","year":"2012","journal-title":"Thromb Res"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.thromres.2012.11.024","article-title":"Thrombosis in acute promyelocytic leukemia","volume":"131","author":"A Rashidi","year":"2013","journal-title":"Thromb Res"},{"issue":"06","key":"ref42","first-page":"567","article-title":"Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia","volume":"75","author":"G Castaman","year":"1990","journal-title":"Haematologica"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"E Truelove","year":"2013","journal-title":"Leukemia"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"M Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref45","first-page":"99","article-title":"Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry","volume":"40","author":"W Ageno","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0049-3848(00)00371-6","article-title":"Reversible portal vein thrombosis complicating induction therapy of acute promyelocytic leukemia","volume":"101","author":"M Colovi\u0107","year":"2001","journal-title":"Thromb Res"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4103\/0973-1482.77077","article-title":"Acute Budd-Chiari syndrome as an initial presentation of acute promyelocytic leukemia","volume":"6","author":"S Bandyopadhyay","year":"2010","journal-title":"J Cancer Res Ther"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.23158","article-title":"Bleeding and thrombosis in acute promyelocytic leukemia","volume":"87","author":"A Choudhry","year":"2012","journal-title":"Am J Hematol"},{"issue":"10","key":"ref49","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/bjs.6319","article-title":"Epidemiology, risk and prognostic factors in mesenteric venous thrombosis","volume":"95","author":"S Acosta","year":"2008","journal-title":"Br J Surg"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11739-010-0413-6","article-title":"Splanchnic vein thrombosis: clinical presentation, risk factors and treatment","volume":"5","author":"V De Stefano","year":"2010","journal-title":"Intern Emerg Med"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-151-3-200908040-00004","article-title":"Etiology, management, and outcome of the Budd-Chiari syndrome","volume":"151","author":"S Darwish Murad","year":"2009","journal-title":"Ann Intern Med"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1478-3231.2008.01838.x","article-title":"Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience","volume":"29","author":"R Rajani","year":"2009","journal-title":"Liver Int"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2018.02.143","article-title":"Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis","volume":"164","author":"A Tufano","year":"2018","journal-title":"Thromb Res"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.13019","article-title":"Review article: portal vein obstruction--epidemiology, pathogenesis, natural history, prognosis and treatment","volume":"41","author":"A Kumar","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"101029","DOI":"10.1155\/2015\/101029","article-title":"Imaging diagnosis of splanchnic venous thrombosis","volume":"2015","author":"S Rajesh","year":"2015","journal-title":"Gastroenterol Res Pract"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2214\/AJR.04.1218","article-title":"Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems","volume":"186","author":"S Rossi","year":"2006","journal-title":"AJR Am J Roentgenol"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00004728-200205000-00014","article-title":"Noninvasive assessment of portomesenteric venous thrombosis: current concepts and imaging strategies","volume":"26","author":"M S Bradbury","year":"2002","journal-title":"J Comput Assist Tomogr"},{"issue":"05","key":"ref58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/1358863X10379673","article-title":"Mesenteric venous thrombosis","volume":"15","author":"I G Harnik","year":"2010","journal-title":"Vasc Med"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10140-009-0807-9","article-title":"Findings in multi-detector row CT with portal phase enhancement in patients with mesenteric venous thrombosis","volume":"16","author":"S Acosta","year":"2009","journal-title":"Emerg Radiol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"C Kearon","year":"2012","journal-title":"Chest"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41424-018-0043-2","article-title":"Long-term outcome of splanchnic vein thrombosis in cirrhosis","volume":"9","author":"M Senzolo","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"06","key":"ref63","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis","volume":"44","author":"L Amitrano","year":"2010","journal-title":"J Clin Gastroenterol"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/gast.2001.21209","article-title":"Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy","volume":"120","author":"B Condat","year":"2001","journal-title":"Gastroenterology"},{"issue":"11","key":"ref65","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/j.1572-0241.2007.01477.x","article-title":"Prognostic factors in noncirrhotic patients with splanchnic vein thromboses","volume":"102","author":"L Amitrano","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hep.23259","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"A Plessier","year":"2010","journal-title":"Hepatology"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/jth.12121","article-title":"Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding","volume":"11","author":"M C Spaander","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref68","first-page":"501","article-title":"Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study","volume":"102","author":"F Dentali","year":"2009","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref69","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation","volume":"18","author":"M Di Nisio","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref70","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"07","key":"ref71","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref72","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref73","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"A A Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"17","key":"ref74","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","article-title":"Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location","volume":"93","author":"D T Janczak","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Y Nagaoki","year":"2018","journal-title":"Hepatol Res"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"V De Stefano","year":"2008","journal-title":"Haematologica"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","article-title":"Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia","volume":"94","author":"J C Hern\u00e1ndez-Boluda","year":"2015","journal-title":"Ann Hematol"},{"issue":"10","key":"ref79","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"V De Stefano","year":"2016","journal-title":"Leukemia"},{"issue":"07","key":"ref80","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018","volume":"8","author":"G Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"A Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"05","key":"ref82","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","article-title":"Risk factors for and management of MPN-associated bleeding and thrombosis","volume":"12","author":"K Martin","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"08","key":"ref83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-019-0225-5","article-title":"Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: a consensus-based position paper","volume":"9","author":"T Barbui","year":"2019","journal-title":"Blood Cancer J"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"A Tefferi","year":"2019","journal-title":"Am J Hematol"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","volume":"2","author":"B R Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref86","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"B T Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref87","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ajh.25270","article-title":"Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger","volume":"93","author":"N Szuber","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1722607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T23:32:59Z","timestamp":1635723179000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1722607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":87,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2021,10,31]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1722607","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]}}}